Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2

Status

Not yet recruiting 2Active not recruiting 2Recruiting 1

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 4Observational 1

Sponsor

Cancer Type

Breast 5

Conditions

Breast Neoplasms 29HER2-positive Breast Cancer 5Neoplasms 3Multiple Myeloma 3Triple Negative Breast Neoplasms 2Prostatic Neoplasms 2Neoplasm Metastasis 2Lymphoma, Non-Hodgkin 2Endometrial Neoplasms 2Colonic Neoplasms 2Brain Neoplasms 2Anatomic Stage II Breast Cancer AJCC v8 2Anatomic Stage I Breast Cancer AJCC v8 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Solid Tumors 1Salivary Gland Neoplasms 1Resectable HER2-positive Breast Cancer 1Rectal Neoplasms 1Pathologic Complete Response 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Meningeal Neoplasms 1Meningeal Carcinomatosis 1Melanoma 1Malignant Solid Neoplasm 1Lymphoma 1

Interventions

pertuzumab 5Trastuzumab 5Docetaxel 3tucatinib 2pyrotinib 1atezolizumab 1Paclitaxel 1Neoadjuvant Therapy 1Injections 1Carboplatin 1Capecitabine 1Ado-Trastuzumab Emtansine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
HER2-positive Breast Cancer × pertuzumab × 90 days × Clear all
NCT03125928 2026-05-22

Clinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer

Fox Chase Cancer Center

Phase 2 Active not recruiting
16 enrolled
Breast

HER2-positive Breast Cancer

NCT06445400 2026-05-13

A Study of BL-M07D1, BL-M07D1+Pertuzumab and BL-M07D1+Pertuzumab+Docetaxel in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer

Sichuan Baili Pharmaceutical Co., Ltd.

Phase 2 Active not recruiting
83 enrolled
Breast

HER2-positive Breast Cancer

NCT07518173 2026-04-08

A Study of BL-M07D1 Combined With Pertuzumab Versus Docetaxel Plus Trastuzumab and Pertuzumab in Patients With First-line HER2-positive Recurrent or Metastatic Breast Cancer

Sichuan Baili Pharmaceutical Co., Ltd.

Phase 3 Not yet recruiting
596 enrolled
Breast

HER2-positive Breast Cancer

NCT07043725 2026-03-27

A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 3 Recruiting
544 enrolled
Breast

HER2-positive Breast Cancer

NCT07470203 2026-03-13

Pyrotinib Combined With Trastuzumab and Pertuzumab for Maintenance Therapy in HER2-Positive Advanced Breast Cancer

Peking University Cancer Hospital & Institute

Not yet recruiting
42 enrolled
Breast

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡